Works matching IS 17762596 AND DT 2025 AND VI 20 AND IP 2

Results: 15

Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach: Continuous Modelling of TMB and ICI Response in NSCLC: M. J. Sorich et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 361, doi. 10.1007/s11523-024-01124-2

By:

Sorich, Michael J.;
Manning-Bennett, Arkady T.;
Li, Lee X.;
Shahnam, Adel;
Kichenadasse, Ganessan;
Karapetis, Christos S.;
Abuhelwa, Ahmad Y.;
McKinnon, Ross A.;
Rowland, Andrew;
Hopkins, Ashley M.

Publication type:

Article

Correction: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence: Second-Line Chemotherapy for Metastatic Breast Cancer: J. Á. García-Saenz et al.

Published in:

2025

By:

García-Saenz, José Ángel;
Rodríguez-Lescure, Álvaro;
Cruz, Josefina;
Albanell, Joan;
Alba, Emilio;
Llombart, Antonio

Publication type:

Correction Notice

The Development of ATM Inhibitors in Cancer Therapy: The Development of ATM Inhibitors in Cancer Therapy: E.A. Ampolini et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 281, doi. 10.1007/s11523-025-01136-6

By:

Ampolini, Elizabeth A.;
Jimenez-Sainz, Judit;
Long, David T.

Publication type:

Article

Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition: Differential IMC Presentation Based on ICI Type: M. Shatila et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 339, doi. 10.1007/s11523-025-01135-7

By:

Shatila, Malek;
Eshaghi, Farzin;
Cruz, Carolina Colli;
Machado, Antonio Pizuorno;
Mathew, Antony;
Zhao, Dan;
Siddiqui, Bilal A.;
Thomas, Anusha Shirwaikar;
Chari, Suresh T.;
Wang, Yinghong

Publication type:

Article

The User's Guide to Amivantamab: The User's Guide to Amivantamab: D. Brazel et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 235, doi. 10.1007/s11523-025-01128-6

By:

Brazel, Danielle;
Smith, Janellen;
Ou, Sai-Hong Ignatius;
Nagasaka, Misako

Publication type:

Article

Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options: Improved Outcomes in Multiple Myeloma: A Comprehensive Review: S. Mettias et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 247, doi. 10.1007/s11523-024-01122-4

By:

Mettias, Sarah;
ElSayed, Adam;
Moore, Jonathan;
Berenson, James R.

Publication type:

Article

Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma: Elranatamab Dosing Regimens to Mitigate CRS: M. Elmeliegy et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 349, doi. 10.1007/s11523-025-01134-8

By:

Elmeliegy, Mohamed;
Viqueira, Andrea;
Vandendries, Erik;
Hickman, Anne;
Conte, Umberto;
Irby, Donald;
Hibma, Jennifer;
Lon, Hoi-Kei;
Piscitelli, Joseph;
Soltantabar, Pooneh;
Skoura, Athanasia;
Jiang, Sibo;
Wang, Diane

Publication type:

Article

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review: Immunomodulation by Ibrutinib in B Cell Malignancies: D. B. Miklos et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 217, doi. 10.1007/s11523-025-01133-9

By:

Miklos, David B.;
Riedell, Peter A.;
Bokun, Alex;
Chavez, Julio C.;
Schuster, Stephen J.

Publication type:

Article

HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions: State of the Art of HER2 Biliary Tract Cancer: S. Camera et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 269, doi. 10.1007/s11523-025-01132-w

By:

Camera, Silvia;
Rossari, Federico;
Foti, Silvia;
Vitiello, Francesco;
Persano, Mara;
Prinzi, Federica Lo;
De Cobelli, Francesco;
Aldrighetti, Luca;
Cascinu, Stefano;
Rimini, Margherita;
Casadei-Gardini, Andrea

Publication type:

Article

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study: Brigatinib for ROS1 NSCLC patients: M. Jean et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 311, doi. 10.1007/s11523-025-01131-x

By:

Mourlanette, Jean;
Rousseau-Bussac, Gaelle;
Mallah, Siham;
Guisier, Florian;
Zalcman, Gerard;
Veillon, Rémi;
Audigier-Valette, Clarisse;
Roa, Magali;
Nicolle, Isabelle;
Doubre, Helene;
Cloarec, Nicolas;
Lamy, Régine;
Morel, Hugues;
Curcio, Hubert;
Lagrange, Aurélie;
Schott, Roland;
Sabatini, Marielle;
Toffart, Anne Claire;
Pinsolle, Julian;
Bennouna, Jaafar

Publication type:

Article

Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events: ICI, SCT, and Inflammatory AE: M. Shatila et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 329, doi. 10.1007/s11523-025-01127-7

By:

Shatila, Malek;
Machado, Antonio Pizuorno;
Shah, Jay;
Rivera, Andres Urias;
Naz, Sidra;
Glombicki, Stephen;
Wali, Sharada;
Lu, Eric;
Short, Nicholas;
Thomas, Anusha;
Zhang, Hao Chi;
Wang, Yinghong

Publication type:

Article

Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study: Immunogenomic Biomarkers of BERIL-1: A. Desilets et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 299, doi. 10.1007/s11523-024-01126-0

By:

Desilets, Antoine;
Lucas, Justin;
Licitra, Lisa F.;
Lu, Sunny;
Tse, Archie;
Tang, Tom;
Dreyer, Kevin;
He, Nanhai;
Birgerson, Lars E.;
Faivre, Sandrine;
Soulières, Denis

Publication type:

Article

Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence: Second-Line Chemotherapy for Metastatic Breast Cancer: J. Á. García-Saenz et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 191, doi. 10.1007/s11523-024-01125-1

By:

García-Saenz, José Ángel;
Rodríguez-Lescure, Álvaro;
Cruz, Josefina;
Albanell, Joan;
Alba, Emilio;
Llombart, Antonio

Publication type:

Article

Bosutinib for the Treatment of CML—Using it Safely: a Podcast: Bosutinib for the Treatment of CML: J. H. Lipton and J. E. Cortes.

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 183, doi. 10.1007/s11523-024-01123-3

By:

Lipton, Jeffrey H.;
Cortes, Jorge E.

Publication type:

Article

Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain: Real-World Experience of Niraparib Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer: M. A. Rodríguez Sagrado et al

Published in:

Targeted Oncology, 2025, v. 20, n. 2, p. 319, doi. 10.1007/s11523-024-01121-5

By:

Rodríguez Sagrado, Miguel Angel;
Alvarez Criado, Javier;
Arenaza Peña, Ainhoa Elisa;
Escudero-Vilaplana, Vicente;
Folguera Olias, Carlos;
Herrero Fernandez, Marta;
Martinez Nieto, Concepción;
Rubio Salvador, Ana Rosa;
Sanmartin Fenollera, Patricia;
Vazquez Castillo, Maria José

Publication type:

Article